Drug intelligence / Profile preview

S6G5T-7

Development stage: Preclinical
Lead developer: Sol-Gel Technologies
Administration: Topical

Overview

S6G5T-7 is an investigational topical drug developed for the treatment of acne vulgaris. Its mechanism of action is currently unknown, and it does not represent a novel mechanistic approach to acne therapy. The drug has not received FDA approval or designation, and there are no known adverse events reported in clinical studies to date. Development is led by Sol-Gel Technologies[1].

Beyond the preview

Go deeper on S6G5T-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S6G5T-7.

Explore the full profile